Systemic treatment of hepatocellular carcinoma: the times they are a-changin'.
作者信息
Campani Claudia, Nault Jean-Charles
机构信息
Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, Team "Functional Genomics of Solid Tumors", Paris, France.
Equipe labellisée Ligue Nationale Contre le Cancer, Labex OncoImmunology, Paris, France.
出版信息
Hepatobiliary Surg Nutr. 2021 Dec;10(6):893-895. doi: 10.21037/hbsn-21-412.
Abstract
摘要
相似文献
1
Systemic treatment of hepatocellular carcinoma: the times they are a-changin'.肝细胞癌的全身治疗：时代正在改变。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):893-895. doi: 10.21037/hbsn-21-412.
2
Times Are A-Changin'.
J Dent Educ. 2017 Aug;81(8):919-920. doi: 10.21815/JDE.017.042.
3
'The times they are a changin'.
Bone Marrow Transplant. 2020 Apr;55(4):673-674. doi: 10.1038/s41409-019-0668-0. Epub 2019 Sep 5.
4
Modeling cancer pain: "the times they are a-changin'".模拟癌症疼痛：“时代在变” 。
Support Care Cancer. 2019 Aug;27(8):3091-3093. doi: 10.1007/s00520-019-04832-y. Epub 2019 May 11.
5
For the times they are a-changin'?时代正在改变？
CVIR Endovasc. 2019;2(1):5. doi: 10.1186/s42155-018-0045-x. Epub 2019 Jan 8.
6
[The times, they are a-changin'].时代在变。
Rev Med Suisse. 2006 Oct 11;2(82):2267.
7
Goodbye print version of the Interactive Journal: the times they are a changin'.告别《互动期刊》的印刷版：时代正在改变。
Interact Cardiovasc Thorac Surg. 2018 Jun 1;26(6):891-893. doi: 10.1093/icvts/ivy169.
8
The times they are a-changin'.时代在变。
Blood. 2011 Feb 10;117(6):1774-5. doi: 10.1182/blood-2010-11-318444.
9
"The times, they are a-changin'"*.时代在变。 （注：原文中“*”在没有更多背景信息下无法准确翻译其指代含义，所以仅翻译了句子主体部分）
Birth. 2011 Jun;38(2):140-1. doi: 10.1111/j.1523-536X.2010.00460.x. Epub 2011 Mar 10.
10
'The Times, They are a Changin': New Editor for CMP in 2019.“时代在变”：2019年《临床微生物学与感染》新主编
Cult Med Psychiatry. 2018 Jun;42(2):205. doi: 10.1007/s11013-018-9582-y.
引用本文的文献
1
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.在中国晚期肝细胞癌中，乐伐替尼与贝伐单抗联合免疫检查点抑制剂及介入三联疗法的疗效比较：CLEAP 2302研究
Liver Cancer. 2025 Apr 3:1-19. doi: 10.1159/000545545.
2
Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.索拉非尼与基于肝动脉灌注化疗的治疗方案用于伴门静脉癌栓的晚期肝细胞癌的疗效比较述评
Gut Liver. 2023 Mar 15;17(2):339-340. doi: 10.5009/gnl220249. Epub 2023 Feb 15.
3
Advances in 3D bioprinting technology for liver regeneration.用于肝脏再生的3D生物打印技术进展。
Hepatobiliary Surg Nutr. 2022 Dec;11(6):917-919. doi: 10.21037/hbsn-22-531.
本文引用的文献
1
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.瑞戈非尼在肝移植后复发肝细胞癌患者索拉非尼治疗后的疗效：一项回顾性研究。
Liver Transpl. 2021 Dec;27(12):1767-1778. doi: 10.1002/lt.26264. Epub 2021 Sep 16.
2
Systemic treatment of hepatocellular carcinoma: An EASL position paper.肝细胞癌的全身治疗：一篇欧洲肝脏研究学会立场文件。
J Hepatol. 2021 Oct;75(4):960-974. doi: 10.1016/j.jhep.2021.07.004. Epub 2021 Jul 10.
3
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.信迪利单抗联合贝伐珠单抗生物类似药（IBI305）对比索拉非尼治疗不可切除肝细胞癌（ORIENT-32）：一项随机、开放标签的2/3期研究
Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.
4
Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses….门静脉高压和肝细胞癌：危险的关联……
Liver Int. 2021 Aug;41(8):1734-1743. doi: 10.1111/liv.14977. Epub 2021 Jun 28.
5
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
6
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.免疫疗法治疗晚期肝细胞癌：关注特殊亚组。
Gut. 2021 Jan;70(1):204-214. doi: 10.1136/gutjnl-2020-321702. Epub 2020 Aug 3.
7
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
8
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
9
Biomarkers for Hepatobiliary Cancers.肝胆肿瘤标志物。
Hepatology. 2021 Jan;73 Suppl 1:115-127. doi: 10.1002/hep.31175. Epub 2020 Nov 29.
10
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.β-连环蛋白激活促进肝癌的免疫逃逸和抗 PD-1 治疗耐药性。
Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.
Zotero 插件